Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza¿s Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.
The unexpected approval of a new multiple myeloma drug could be a big upside surprise for Onyx Pharma shares.
Verastem is a buy only because sell-side analysts are afraid to anger their investment banking overlords.
An investor explains the short thesis for Seattle Genetics and its cancer drug Adcetris.
An investor finds few reasons to buy three pancreatic cancer drug stocks -- Clovis, Celgene and Threshold Pharma.
The amyloid beta hypothesis doesn't explain Alzheimer's, which leaves Elan and its partners in trouble.
Finding treatable Hep C patients will be harder than expected, so buying into Gilead's current valuation may not be wise.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.